Onusa Chantanapongwanij
@Artia Global Partners Lp
Latest period2024 - Q3ReportedManaged Assets$366.884MTotal holdings44
Assets growth rate-29.08%Assets growth rate (2-Q avg)-12.54%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Artia Global Partners Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 44 positions.
Assets under management
The assets under management (AUM) of Artia Global Partners Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 366.884M in assets, with a quarterly growth rate of -29.08% and a 2-quarter average growth rate of -12.54%. The portfolio is managed by Onusa Chantanapongwanij, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
LLYEli Lilly & Co
| 25.99% | $95.321M 107,593 shares@ $885.94 avg price | Increased 16.2% |
NVONovo-nordisk A S
| 24.08% | $88.319M 741,743 shares@ $119.07 avg price | Increased 7.23% |
VKTXViking Therapeutics Inc
| 9.2% | $33.737M 532,879 shares@ $63.31 avg price | Increased 17.64% |
ITCIIntra-cellular Therapies Inc
| 4.32% | $15.843M 216,519 shares@ $73.17 avg price | |
AZNAstrazeneca Plc
| 4.06% | $14.861M 190,752 shares@ $77.91 avg price | |
SLNOSoleno Therapeutics Inc
| 3.78% | $13.856M 274,424 shares@ $50.5 avg price | Increased 190.63% |
ALNYAlnylam Pharmaceuticals Inc
| 2.63% | $9.626M 35,000 shares@ $275.03 avg price | |
VRTXVertex Pharmaceuticals Inc
| 2.4% | $8.79M 18,900 shares@ $465.08 avg price | |
PCVXVaxcyte Inc
| 2.38% | $8.714M 76,255 shares@ $114.28 avg price | |
ARGXArgenx Se
| 2.24% | $8.206M 15,138 shares@ $542.08 avg price |